If we consider, for example, heterologous insulin biosynthesis in E. coli, we often find that a strategy based on synthesizing the target protein by expression plasmids has simply been adopted. But wouldn't that be a problem in terms of plasmid stability during continuous production on an industrial scale? Shouldn't such operations be performed with modifications at the chromosome level? There are definitely different nuances in other hormones, enzymes and proteins, thus I would appreciate it if you could explain by giving some examples.
Thanks in advance..
Dear Abdurrahman Aygül,
Plasmid maintenance in the lab is usually achieved by means of an antibiotic resistance marker present on the plasmid. However, for industrial processes, selection by means of a prototrophic marker is usually preferred due to the high cost of antibiotics, which in addition are problematic contaminants in the effluents,
- Badges
- Science topic